Autoimmune Polyglandular Syndrome Type 1 (APS-1), also known as Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), is a rare autosomal recessive disorder caused by mutations in the AIRE (Autoimmune Regulator) gene. This syndrome is characterized by a triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency, although it can affect multiple other organ systems. APS-1 arises from a failure of central immune tolerance, resulting in autoimmunity against various endocrine and non-endocrine tissues. The clinical presentation and disease progression are highly variable, necessitating a comprehensive and individualized approach to diagnosis and management. Treatment primarily involves hormone replacement therapies, such as glucocorticoids for adrenal insufficiency, calcium and vitamin D supplements for hypoparathyroidism, and antifungal agents for candidiasis. Immunosuppressive therapies may be required for severe autoimmune complications. Despite advances in understanding the disease's genetic and immunological basis, APS-1 remains a challenging condition due to its rarity and multisystem involvement. Early diagnosis, multidisciplinary care, and patient education are crucial for optimizing outcomes and preventing life-threatening complications. Emerging therapeutic strategies, such as targeted immunomodulation and gene therapies, hold promise for more effective disease management in the future.

Keywords :Autoimmune Polyglandular Syndrome, Type 1 AIRE gene mutations, Multisystem autoimmunity, life-threatening complications, endocrine and non-endocrine tissues.

🔒 This is a subscription article

Full text is available to subscribers and institutional members. Please choose an option below to access it.

Autoimmune Polyglandular Syndrome Type 1 (APS-1), also known as Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), is a rare autosomal recessive disorder caused by mutations in the AIRE (Autoimmune Regulator) gene. This syndrome is characterized by a triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency, although it can affect multiple other organ systems. APS-1 arises from a failure of central immune tolerance, resulting in autoimmunity against various endocrine and non-endocrine tissues. The clinical presentation and disease progression are highly variable, necessitating a comprehensive and individualized approach to diagnosis and management. Treatment primarily involves hormone replacement therapies, such as glucocorticoids for adrenal insufficiency, calcium and vitamin D supplements for hypoparathyroidism, and antifungal agents for candidiasis. Immunosuppressive therapies may be required for severe autoimmune complications. Despite advances in understanding the disease's genetic and immunological basis, APS-1 remains a challenging condition due to its rarity and multisystem involvement. Early diagnosis, multidisciplinary care, and patient education are crucial for optimizing outcomes and preventing life-threatening complications. Emerging therapeutic strategies, such as targeted immunomodulation and gene therapies, hold promise for more effective disease management in the future.

Keywords :Autoimmune Polyglandular Syndrome, Type 1 AIRE gene mutations, Multisystem autoimmunity, life-threatening complications, endocrine and non-endocrine tissues.

🔒 This is a subscription article

Full text is available to subscribers and institutional members. Please choose an option below to access it.